W. Fraser Symmans
University of Texas MD Anderson Cancer Center
290 Papers
1.1K Citations
W. Fraser Symmans is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 71, co-authored 184 publications. Previous affiliations of W. Fraser Symmans include University of Münster.
Chat about Author
Papers
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
Mohamed Amgad,Elisabeth Specht Stovgaard,Eva Balslev,Jeppe Thagaard,Weijie Chen,Sarah N Dudgeon,Ashish Sharma,Jennifer K. Kerner,Carsten Denkert,Carsten Denkert,Carsten Denkert,Yinyin Yuan,Khalid AbdulJabbar,Stephan Wienert,Peter Savas,Peter Savas,Leonie Voorwerk,Andrew H. Beck,Anant Madabhushi,Anant Madabhushi,Johan Hartman,Manu M. Sebastian,Hugo M. Horlings,Jan Hudecek,Francesco Ciompi,David Moore,Rajendra Singh,Elvire Roblin,Marcelo Luiz Balancin,Marie-Christine Mathieu,Jochen K. Lennerz,Pawan Kirtani,I-Chun Chen,Jeremy P Braybrooke,Jeremy P Braybrooke,Giancarlo Pruneri,Sandra Demaria,Sylvia Adams,Stuart J. Schnitt,Sunil R. Lakhani,Federico Rojo,Laura Comerma,Sunil S. Badve,Mehrnoush Khojasteh,W. Fraser Symmans,Christos Sotiriou,Paula I. Gonzalez-Ericsson,Katherine L. Pogue-Geile,Rim S. Kim,David L. Rimm,Giuseppe Viale,Stephen M. Hewitt,John M. S. Bartlett,John M. S. Bartlett,Frédérique Penault-Llorca,Shom Goel,Huang-Chun Lien,Sibylle Loibl,Zuzana Kos,Sherene Loi,Sherene Loi,Matthew G. Hanna,Stefan Michiels,Stefan Michiels,Marleen Kok,Torsten O. Nielsen,Alexander J. Lazar,Zsuzsanna Bago-Horvath,Loes F. S. Kooreman,Jeroen van der Laak,Jeroen van der Laak,Joel H. Saltz,Brandon D. Gallas,Uday Kurkure,Michael Barnes,Roberto Salgado,Lee Cooper +76 more
- 12 May 2020
TL;DR: The benefits of computational TILs assessment, the readiness of Tils scoring for computational assessment, and considerations for overcoming key barriers to clinical translation in this arena are outlined.
136
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Abigail S. Caudle,Ana M. Gonzalez-Angulo,Kelly K. Hunt,Ping Liu,Lajos Pusztai,W. Fraser Symmans,Henry Mark Kuerer,Elizabeth A. Mittendorf,Gabriel N. Hortobagyi,Funda Meric-Bernstam +9 more
TL;DR: Novel molecular predictors are needed to identify patients at risk for progression on standard NCT, including race, advanced tumor stage, high nuclear grade, high Ki-67 score, and ER/PR negativity.
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer
Fabrice Andre,Christos Hatzis,Keith Anderson,Christos Sotiriou,Chafika Mazouni,Jaime A. Mejia,Bailiang Wang,Gabriel N. Hortobagyi,W. Fraser Symmans,Lajos Pusztai +9 more
TL;DR: This study suggests that high tau mRNA expression in ER-positive breast cancer indicates an endocrine-sensitive but chemotherapy-resistant disease, and low tau expression identifies a subset of ER- positive cancers that have poor prognosis with tamoxifen alone and may benefit from taxane-containing chemotherapy.
132
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
Elena Provenzano,Veerle Bossuyt,Giuseppe Viale,David Cameron,Sunil V. Badve,Carsten Denkert,Gaëtan MacGrogan,Frédérique Penault-Llorca,Judy C. Boughey,Giuseppe Curigliano,J. Michael Dixon,Laura J. Esserman,Gerd Fastner,Thorsten Kuehn,Florentia Peintinger,Gunter von Minckwitz,Julia White,Wei Yang,W. Fraser Symmans +18 more
- 01 Jul 2015
TL;DR: A review of standard operating procedures used by 28 major neoadjuvant breast cancer trials and/or 25 sites involved in such trials identified marked variability in specimen handling and histologic reporting as mentioned in this paper.
115
Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor–Positive Breast Cancer
Enrique Fuentes-Mattei,Guermarie Velazquez-Torres,Liem Phan,Fanmao Zhang,Ping Chieh Chou,Ji Hyun Shin,Hyun Ho Choi,Jiun Sheng Chen,Ruiying Zhao,Jian Chen,Christopher Gully,Colin Carlock,Yuan Qi,Ya Zhang,Yun Wu,Francisco J. Esteva,Yongde Luo,Wallace L. McKeehan,Joe Ensor,Gabriel N. Hortobagyi,Lajos Pusztai,W. Fraser Symmans,Mong Hong Lee,Sai Ching J. Yeung +23 more
TL;DR: Adipokine secretion and AKT/mTOR activation play important roles in obesity-accelerated breast cancer aggressiveness in addition to hyperinsulinemia, estrogen signaling, and inflammation.